Sarepta Therapeutics, Inc. (SRPT) News
Track canonical SquawkNews coverage tagged to SRPT, Sarepta Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 9 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
SRPT - Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
SRPT - Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
EARNINGS | Aug 05, 2026, 08:20 PM UTC
L
SRPT - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SRPT - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
EQUITY | Jul 29, 2026, 09:05 PM UTC
L
SRPT Sarepta Therapeutics appoints Michael severino, M.D., Chief Executive Officer Sarepta Therapeutics - Doug ingram to retire and serve as
SRPT Sarepta Therapeutics appoints Michael severino, M.D., Chief Executive Officer Sarepta Therapeutics - Doug ingram to retire and serve as advisor until end of 2026
EQUITY | Jul 27, 2026, 12:35 PM UTC
L
SRPT appoints Michael Severino as CEO.
SRPT appoints Michael Severino as CEO.
EQUITY | Jul 27, 2026, 12:34 PM UTC
L
SRPT Reiterate Sell, $14 PT – expect continued headwinds for exondys and elevidys @ DBAB
SRPT Reiterate Sell, $14 PT – expect continued headwinds for exondys and elevidys @ DBAB
EQUITY | Jul 27, 2026, 12:19 PM UTC
L
Tractor Supply downgrade, Five Below upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: Mizuho upgraded Five Below (FIVE)
EQUITY | Jul 09, 2026, 01:47 PM UTC
H
Sarepta price target lowered to $20 from $23 at Piper Sandler
Piper Sandler lowered the firm's price target on Sarepta to $20 from $23 and keeps a Neutral rating on the shares. The firm lowers its Q2 Elevidys U.S. revenue estimate to $93M from $102.9M and collaboration revenue to $
EQUITY | Jul 09, 2026, 11:15 AM UTC
L
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs
The U.S. Food and Drug Administration (FDA) accepted on Tuesday Sarepta Therapeutics Inc.’s (NASDAQ: SRPT ) supplemental New Drug Applications seeking to convert the accelerated approvals of AMONDYS 45 (casimersen) and V
GEOPOLITICS | Jun 30, 2026, 04:44 PM UTC
L
Sarepta Therapeutics Says FDA Accept sNDAs For AMONDYS 45 And VYONDYS 53 For Treatment Of Duchenne Muscular Dystrophy; PDUFA Target Action D
Accepted for review with target action date of February 28, 2027 Sarepta Therapeutics, Inc. (NASDAQ: SRPT ), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Adminis
REGULATION | Jun 30, 2026, 12:38 PM UTC